Peer Review History

Original SubmissionNovember 8, 2022
Decision Letter - Rabia Hussain, Editor

PONE-D-22-30776Iranian Primary Healthcare System's Response to COVID-19Pandemic using Healthcare Incident Command SystemPLOS ONE

Dear Dr. Motlagh,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Please make the changes as suggested by the reviewer.

Revise the abstract and other sections

==============================

Please submit your revised manuscript by Mar 24 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Rabia Hussain, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. During your revisions, please note that a simple title correction is required: There is a missing space in the title "COVID-19Pandemic", please correct this in the online submission information."

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"This study was carried out with the support of the Kurdistan University of Medical Sciences and funded by Disaster Risk Management Office in Ministry of Health."

We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

5. Thank you for stating the following financial disclosure:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

a)        Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b)        State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c)        If any authors received a salary from any of your funders, please state which authors and which funders.

d)        If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

7. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Additional Editor Comments:

Dear Authors,

Please revise your manuscript as suggested by the reviewers.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: “Iranian Primary Healthcare System’s Response to COVID-19Pandemic

using Healthcare Incident Command System”

Comments on the paper by Arezoo Yari et al

submitted to PLOS ONE (MS number PONE-D-22-30776)

_______________________________________________________

Author : P.N. Lee

Date : 23rd November 2022

While the paper is generally well written and the results clear and well analysed, there are a few points that demand some attention. These are considered below in the order they appear in the paper and not in order of importance.

1. The full title would be better if there were a space between “COVID-19” and “Pandemic” and if the word “the” was inserted after “Response to” and after “using”.

2. I found the Methods section of the Abstract somewhat confusing at first, as it stated that some DHNs had an active HICS and some did not, so how could data on HICS be collected from those that did not have an active HICS? Later on in the paper it appears that data were in fact collected from all the 60 DHNs. It might also be a good idea to mention the number of DHNs with active and inactive HICS. Perhaps the Method section might read something like the following:

“Methods: The study was performed in Iran in June 2020 in 60 DHNs, 41 of which had an active HICS. Data were collected on eight HCIS constructs from all 60 DHNs by trained crisis management experts to evaluate the effects of HICS use on management of the COVID-19 pandemic”.

3. The results might better start:

“For all the 60 DHNs, the mean score of the COVID-19 incident command and management was 78.79 ± 11.90 (range 20-100); with mean scores highest for organizational support and cooordination and lowest for logistic and planning”.

4. While it is clear enough from Tables 2 and 3 that scores on total incident command and the other seven dimensions were clearly higher in DHNs with an active HICS (p<0.01 in all cases), I wonder whether it is enough to infer from this that HICS should always be active. The study does not investigate health endpoints, and it would be interesting to know, for example, whether the 41 DHNs with active HICS had a lower mortality rate among patients admitted for COVID-19 than did the 19 DHNs without active HICS. Does having active HICS work as regards the virus?

5. Near the end of the Introduction section, there is a statement that MOHME “necessitated that all health systems use HICS as an essential infrastructure since 2011” and that the following the outbreak of SARS-COV-2 in Iran, “the authorities officially announced the activation of HICS in the healthcare system on all levels”. That being the case, how did it come about that 19 of the 60 DHNs did not use the HICS?

6. Under “data analysis” it is made clear that the classification of total incident management and command into low, average and high was based on putting the bottom 25% as low, the top 25% as high and the rest as average. But there is nothing about how low, average and high were defined for the seven constructs from organizational support to human resource management. It would be useful to give fuller details as to how these scores were derived, perhaps as a supplementary file which details the questions actually asked and the possible replies.

7. In the Discussion section there is a paragraph starting “In this study, among the studied dimensions, the lowest command scores in the DHNs belonged to the planning dimension”. But according to Table 1, the lowest score is for the logistic dimension.

8. While the paper is well written, the last paragraph of the introduction could be improved by replacing “didn’t” by “did not”, and by inserting “been” before “considered in our study”.

Reviewer #2: Dear Authors

This is good effort to explain Iranian Primary Healthcare System's Response to COVID-19Pandemic using Healthcare Incident Command System.

It is well written .

But in my opinion it is more useful for local Iranian Journal.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Peter N Lee

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

PLOS ONE JOURNAL

Dear Editor

Thank you very much for considering our manuscript for publication. We appreciate the comments made by the respected the reviewers.

We carefully read the comments and considered the comments and made changes and /or made our manuscript clearer accordingly.

With respect to the opinions of the reviewers and editors, the article was revised. Please note that all changes are done in the main text.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf

and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Thanks for your comment. Based on your comment we revised our article based on The PLOS ONE style templates.

2. During your revisions, please note that a simple title correction is required: There is a missing space in the title "COVID-19Pandemic", please correct this in the online submission information."

Response: Thanks for your comment. Based on your comment we made this correction on the title and added the space in the tittle "COVID-19 Pandemic", in the online submission information.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"This study was carried out with the support of the Kurdistan University of Medical Sciences and funded by Disaster Risk Management Office in Ministry of Health."

We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: Thanks for your comment. Based on your comment we revised the Acknowledgments Section of my manuscript and removed any funding-related text from the manuscript. Also, we have added and highlighted my amended statements (related to the funding section) in the cover letter, we hope this section will be added to the online version.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Response: Thanks for your comment. Based on your comment we moved our ethics statement to the method section and deleted it from last section in the article. these changes are highlighted in yellow color in the last part of methods section, page 9, lines 6-15.

5. Thank you for stating the following financial disclosure:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Response: Thanks for your comment. Based on your comment we have added and highlighted my amended statements (related to the funding section) in the cover letter, we hope this section will be added to the online version.

6. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

Response: Thanks for your comment. Based on your comment we added an ORCID iD for the corresponding author Editorial Manager account.

7. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response: Thanks for your comment. Based on your comment we update and added the data availability statement section with the name and contact details of the local ethics committee upon our cover letter. the data availability statement section is shown in red color and highlighted with yellow color in cover letter.

Additional Editor Comments:

Dear Authors,

Please revise your manuscript as suggested by the reviewers.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Response: Thanks for your comment. Based on your comment we revised our manuscript as suggested by the reviewers. Also, we did not edit the HTML markup suggested by you.

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

Responses: Thanks for your comment. In this cross-sectional study, we tried to carry out all the stages of implementation technically according to the principles of a cross-sectional study.

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

Responses: Thanks for your comment. All statistical analysis were performed in consultation with one of the authors who has expertise in statistics.

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

Responses: Thanks for your comment. we cannot share our data publicly but the data will be made available on request through Kurdistan University of Medical Sciences Ethics Committee, to researchers who meet the criteria for access to confidential data. The requests can be sent to Kurdistan University of Medical Sciences Ethics Committee email: ethiccommittee@muk.ac.ir.

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Responses: Thanks for your comment.________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: “Iranian Primary Healthcare System’s Response to COVID-19Pandemic

using Healthcare Incident Command System”

Comments on the paper by Arezoo Yari et al

submitted to PLOS ONE (MS number PONE-D-22-30776)

_______________________________________________________

Author : P.N. Lee

Date : 23rd November 2022

While the paper is generally well written and the results clear and well analysed, there are a few points that demand some attention. These are considered below in the order they appear in the paper and not in order of importance.

1. The full title would be better if there were a space between “COVID-19” and “Pandemic” and if the word “the” was inserted after “Response to” and after “using”.

Responses: Thanks for your comment. Based on your comment we made this correction on the title and added the space in the tittle "COVID-19 Pandemic". Also, we inserted the word “the” after “Response to” and after “using”. These changes are highlighted in yellow color in the title.

2. I found the Methods section of the Abstract somewhat confusing at first, as it stated that some DHNs had an active HICS and some did not, so how could data on HICS be collected from those that did not have an active HICS? Later on in the paper it appears that data were in fact collected from all the 60 DHNs. It might also be a good idea to mention the number of DHNs with active and inactive HICS. Perhaps the Method section might read something like the following:

“Methods: The study was performed in Iran in June 2020 in 60 DHNs, 41 of which had an active HICS. Data were collected on eight HCIS constructs from all 60 DHNs by trained crisis management experts to evaluate the effects of HICS use on management of the COVID-19 pandemic”.

Responses: Thanks for your comment. Based on your comment we revised the Methods section of the Abstract. These changes are highlighted in yellow color in the abstract section, page 2, lines 7-10.

3. The results might better start:

“For all the 60 DHNs, the mean score of the COVID-19 incident command and management was 78.79 ± 11.90 (range 20-100); with mean scores highest for organizational support and cooordination and lowest for logistic and planning”.

Responses: Thanks for your comment. Based on your comment we revised the result section of the Abstract. These changes are highlighted in yellow color in the abstract section, page 2, lines 10-12.

4. While it is clear enough from Tables 2 and 3 that scores on total incident command and the other seven dimensions were clearly higher in DHNs with an active HICS (p<0.01 in all cases), I wonder whether it is enough to infer from this that HICS should always be active. The study does not investigate health endpoints, and it would be interesting to know, for example, whether the 41 DHNs with active HICS had a lower mortality rate among patients admitted for COVID-19 than did the 19 DHNs without active HICS. Does having active HICS work as regards the virus?

Responses: Thanks for your comment. It is definitely very useful to examine and compare the investigate health endpoints caused by COVID-19 in two groups of DHNs, but it was not the subject of this research, in this study only the management and commanding of the COVID-19 pandemic was investigated in two groups of DHNs.

5. Near the end of the Introduction section, there is a statement that MOHME “necessitated that all health systems use HICS as an essential infrastructure since 2011” and that the following the outbreak of SARS-COV-2 in Iran, “the authorities officially announced the activation of HICS in the healthcare system on all levels”. That being the case, how did it come about that 19 of the 60 DHNs did not use the HICS?

Responses: Thanks for your comment. Based on your comment, we rechecked the instructions and found the following: Although this system was announced in the country's health system in 2011, its use was not mandatory due to some practical problems therefore the Ministry of Health and medical education has been trying to commercialize its use through encouragement. Therefore, we corrected and edited the sentences related to this part, these corrections are highlighted in yellow color in the introduction section, page 5, lines 8-10.

6. Under “data analysis” it is made clear that the classification of total incident management and command into low, average and high was based on putting the bottom 25% as low, the top 25% as high and the rest as average. But there is nothing about how low, average and high were defined for the seven constructs from organizational support to human resource management. It would be useful to give fuller details as to how these scores were derived, perhaps as a supplementary file which details the questions actually asked and the possible replies.

Responses: Thanks for your comment. Based on your comment we added three files with explanations about how these scores were derived as a supplementary file which details the questions actually asked and the possible replies.

7. In the Discussion section there is a paragraph starting “In this study, among the studied dimensions, the lowest command scores in the DHNs belonged to the planning dimension”. But according to Table 1, the lowest score is for the logistic dimension.

Responses: Thanks for your comment. Based on your comment we revised this section. these corrections are highlighted in yellow color in the discussion section, page 15, lines 22-23.

8. While the paper is well written, the last paragraph of the introduction could be improved by replacing “didn’t” by “did not”, and by inserting “been” before “considered in our study”.

Responses: Thanks for your comment. Based on your comment we replaced “didn’t” by “did not”, and inserted “been” before “considered in our study”. these corrections are highlighted in yellow color in the last paragraph of the discussion section, page 17, lines 4 and 7.

Reviewer #2: Dear Authors

This is good effort to explain Iranian Primary Healthcare System's Response to COVID-19Pandemic using Healthcare Incident Command System.

It is well written .

But in my opinion it is more useful for local Iranian Journal.

Responses: Thanks for your comment. our study was the evaluation of various dimensions of COVID-19 crisis command based on a global algorithm, which encompassed all the aspects of incident command and management in an emergency. Therefore, the results of this study can be used anywhere in the world. this study is effective in improving our understanding of the role of HICS systems in controlling the COVID-19 pandemic.

________________________________________

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Peter N Lee

Reviewer #2: No

Attachments
Attachment
Submitted filename: Response to Reviewers. number3.docx
Decision Letter - Masoud Behzadifar, Editor

Iranian primary healthcare system's response to the COVID-19 pandemic using the healthcare incident command system

PONE-D-22-30776R1

Dear Dr. Motlagh,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Masoud Behzadifar

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for addressing the comments I made on the version of the paper as submitted originally. I have no further comments

Reviewer #2: Dear Authors

You said that your study was the evaluation of various

dimensions of COVID-19 crisis command based on a global algorithm, which

encompassed all the aspects of incident command and management in an emergency.

Therefore, the results of this study can be used anywhere in the world. this study is

effective in improving our understanding of the role of HICS systems in controlling the

COVID-19 pandemic.

But I am not sure about your response.

________________________________________

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Peter N Lee

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Masoud Behzadifar, Editor

PONE-D-22-30776R1

Iranian primary healthcare system's response to the COVID-19 pandemic using the healthcare incident command system

Dear Dr. Motlagh:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Masoud Behzadifar

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .